What the quality statement means for service providers, healthcare practitioners, and commissioners .. 
Introduction Introduction
This quality standard covers the identification and management of heterozygous familial hypercholesterolaemia (FH) in adults, young people and children. Homozygous FH has been excluded from this quality standard because it has a low incidence and people with homozygous FH need specialist care. Please see the NICE guideline on familial hypercholesterolaemia for recommendations on the diagnosis and treatment of homozygous FH. For more information see the scope of the quality standard.
Why this quality standard is needed
FH is an inherited condition caused by an alteration in a gene, which results in a high cholesterol concentration in the blood. Raised cholesterol concentrations are present from birth and lead to early development of atherosclerosis and coronary heart disease. The condition is transmitted from generation to generation in such a way that siblings and children of a person with FH have a 1 in 2 chance (50:50 risk) of also having FH.
Most people with FH have inherited an altered gene for FH in an autosomal dominant pattern from only 1 parent and are therefore 'heterozygous'. Occasionally, a person will inherit an altered gene from both parents and will have 'homozygous' FH or 'compound heterozygous' FH. Homozygous FH is rare, with an incidence of approximately one in a million.
The prevalence of heterozygous FH in the UK population is estimated to be 1 in 500, which means that approximately 120,000 people are expected to be affected [1] . However, more than 80% of these are currently undiagnosed and untreated. If left untreated, more than 50% of men with heterozygous FH will develop coronary heart disease by the age of 50 years and more than 50% of women by the age of 60 years [2] . Life expectancy is restored to near normal with early preventive treatment, particularly statin treatment and smoking cessation.
The importance of better identification of families/individuals at very high risk of cardiovascular disease, including those with FH, is recognised in the Department of Health's Cardiovascular Disease Outcomes Strategy.
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How this quality standard supports delivery of outcome frameworks NICE quality standards are a concise set of prioritised statements designed to drive measureable quality improvements within a particular area of health or care. They are derived from high-quality guidance, such as that from NICE or other sources accredited by NICE. This quality standard, in conjunction with the guidance on which it is based, should contribute to the improvements outlined in the following outcomes framework published by the Department of Health:
NHS Outcomes Framework 2013/14 (Department of Health, November 2012) Table 1 shows the outcomes, overarching indicators and improvement areas from the framework that the quality standard could contribute to achieving.
T Table 1 able 1 
Coordinated services
The quality standard for FH specifies that services should be commissioned from and coordinated across all relevant agencies encompassing the whole FH care pathway. A person-centred, integrated approach to providing services is fundamental to delivering high-quality care to people with FH.
The Health and Social Care Act 2012 sets out a clear expectation that the care system should consider NICE quality standards in planning and delivering services, as part of a general duty to secure continuous improvement in quality. Commissioners and providers of health and social care
should refer to the library of NICE quality standards when designing high-quality services. Other quality standards that should also be considered when choosing, commissioning or providing a high-quality FH service are listed in related quality standards.
Training and competencies
The quality standard should be read in the context of national and local guidelines on training and competencies. All healthcare practitioners involved in assessing, caring for and treating people with FH should have sufficient and appropriate training and competencies to deliver the actions and interventions described in the quality standard. 181-5.
[2]
Slack J (1969) Risks of ischaemic heart-disease in familial hyperlipoproteinaemia states. Lancet 2:
1380-2. 
Quality measures
Structure Structure
Evidence of local arrangements to ensure that adults with a baseline total cholesterol above 7.5 mmol/l are assessed for a clinical diagnosis of FH.
Data sour
Data source: ce: Local data collection.
Process Process
Proportion of adults with a baseline total cholesterol above 7.5 mmol/l who are assessed for a clinical diagnosis of FH.
Numerator -The number of people in the denominator assessed for a clinical diagnosis of FH.
Denominator -The number of adults with a baseline total cholesterol above 7.5 mmol/l.
Data sour
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What the quality statement means for service providers, general practitioners, and commissioners
Service pro Service providers viders ensure that systems are in place for adults with a baseline total cholesterol above 7.5 mmol/l to be assessed for a clinical diagnosis of FH.
Gener General pr al practitioners actitioners assess adults with a baseline total cholesterol above 7.5 mmol/l for a clinical diagnosis of FH.
Commissioners Commissioners ensure that they commission services that identify and assess adults with a baseline total cholesterol above 7.5 mmol/l for a clinical diagnosis of FH.
What the quality statement means for patients, service users and carers
Adults with a total cholesterol abo Adults with a total cholesterol abov ve 7.5 e 7.5 mmol/l before treatment mmol/l before treatment have an assessment for FH.
Source guidance
Familial hypercholesterolaemia: identification and management (NICE guideline CG71), recommendations 1.1.1, 1.1.2, 1.1.4, 1.1.5 and 1.1.9 
Definitions of terms used in this quality statement
Process Process
Proportion of people with a clinical diagnosis of FH referred for specialist assessment.
Numerator -The number of people in the denominator referred for specialist assessment.
Denominator -The number of people with a clinical diagnosis of FH.
Data sour
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Outcome Outcome
Ratio of observed to estimated numbers of people with FH, using an estimate based on the area's estimated prevalence of FH (based on 1 in 500) and population size. Children refers to people younger than 10, young people refers to those aged 10 up to and including age 15, and adults refers to people aged 16 and older.
Quality statement 3: DNA testing Quality statement 3: DNA testing
Quality statement
People with a clinical diagnosis of familial hypercholesterolaemia (FH) are offered DNA testing as part of a specialist assessment.
Rationale
DNA testing is important because it increases the certainty of a diagnosis of FH and allows the identification of affected and unaffected relatives through cascade testing.
Quality measures
Structure Structure
Evidence of local arrangements to ensure that people with a clinical diagnosis of FH are offered DNA testing as part of a specialist assessment. Numerator -The number of people in the denominator receiving DNA testing as part of a specialist assessment.
Data sour
Data sour Data source: ce:
Local data collection using a dedicated database.
b) Proportion of people with a clinical diagnosis of FH receiving DNA testing as part of a specialist assessment who give informed consent for the test.
Numerator -The number of people in the denominator who give informed consent for the test.
Denominator -The number of people with a clinical diagnosis of FH receiving DNA testing as part
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Data sour Data source: ce:
Outcome Outcome
Patient satisfaction with process of informed consent.
Data sour
What the quality statement means for service providers, healthcare practitioners, and commissioners
Service pro Service providers viders ensure that systems are in place for people with a clinical diagnosis of FH to be offered DNA testing as part of a specialist assessment.
Specialists with e Specialists with expertise in FH xpertise in FH offer DNA testing to people with a clinical diagnosis of FH as part of a specialist assessment.
Commissioners Commissioners ensure that they commission services that offer DNA testing to people with a clinical diagnosis of FH as part of a specialist assessment.
What the quality statement means for patients, service users and carers
P People who are giv eople who are given a clinical diagnosis of FH en a clinical diagnosis of FH because they have high cholesterol and family history or other signs are offered DNA testing as part of a specialist assessment.
Source guidance
Familial hypercholesterolaemia: identification and management (NICE guideline CG71), recommendation 1.1.6
Definitions of terms used in this quality statement
Familial h Familial hypercholesterolaemia (FH) ypercholesterolaemia (FH)
FH relates to heterozygous FH only.
Familial hypercholesterolaemia (QS41)
Quality statement 4: Diagnosis in children under 10 Quality statement 4: Diagnosis in children under 10 y years ears
Quality statement
Children at risk of familial hypercholesterolaemia (FH) are offered diagnostic tests by the age of 10 years.
Rationale
Children with FH begin to develop cardiovascular disease before clinical signs appear, with thickening of the carotid artery wall identifiable by the age of 10 years. Diagnosis by the age of 10 years allows lifestyle changes and tailored therapy if indicated, which will reduce long-term problems associated with high cholesterol and improve long-term health.
Quality measures
Structure Structure
Evidence of local arrangements to ensure that children at risk of FH are offered diagnostic tests by the age of 10 years.
Data sour
Process Process
Proportion of children at risk of FH who receive a specified diagnostic test by the age of 10 years.
Numerator -The number of people in the denominator who had received a specified diagnostic test.
Denominator -The number of children aged 10 years at risk of FH.
Data sour
Outcome Outcome
Ratio of observed to estimated numbers of children at risk of FH, using an estimate based on the area's estimated prevalence of FH (based on 1 in 500) and population size. 
What the quality statement means for service providers, healthcare practitioners, and commissioners
Service Servicepro providers viders ensure that systems are in place for children at risk of FH to be offered diagnostic tests by the age of 10 years.
Specialist with e Specialist with expertise in FH in children and y xpertise in FH in children and young people oung people offer children at risk of FH diagnostic tests by the age of 10 years.
Commissioners Commissioners ensure that they commission services that offer children at risk of FH diagnostic tests by the age of 10 years.
What the quality statement means for patients, service users and carers
Children at risk of FH Children at risk of FH because they have 1 parent with the condition are offered diagnostic tests by the age of 10 years.
Source guidance
Familial hypercholesterolaemia: identification and management (NICE guideline CG71), recommendation 1.1.15 
Definitions of terms used in this quality statement
Quality statement
Relatives of people with a confirmed diagnosis of monogenic familial hypercholesterolaemia (FH) are offered DNA testing through a nationwide, systematic cascade process.
Rationale
Most people in the UK with FH are undiagnosed. Cascade testing has been shown to be effective for identifying people with FH, especially when provided nationwide. Nationwide cascade testing ensures that all family members can access DNA testing wherever they live.
Quality measures
Structure Structure
Evidence of local arrangements to ensure that relatives of people with a confirmed diagnosis of monogenic FH are offered DNA testing through a nationwide systematic cascade processes.
Data sour
Process Process a) Proportion of untested first-degree relatives of people with a confirmed diagnosis of monogenic FH who are offered cascade testing.
Numerator -The number of people in the denominator offered cascade testing.
Denominator -The number of untested first-degree relatives of people with a confirmed diagnosis of monogenic FH.
Data sour Data source: ce:
b) Proportion of at-risk, untested, second-and third-degree relatives of people with a confirmed diagnosis of monogenic FH who are offered cascade testing.
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Denominator -The number of at-risk, untested second-and third-degree relatives of people with a confirmed diagnosis of monogenic FH.
Data sour Data source: ce:
c) Proportion of untested first-degree relatives of people with a confirmed diagnosis of monogenic FH who receive cascade testing.
Numerator -The number of people in the denominator receiving cascade testing.
d) Proportion of at-risk, untested, second-and third-degree relatives of people with a confirmed diagnosis of monogenic FH who receive cascade testing.
Outcome Outcome
Prevalence of FH.
Data sour Data source: ce:
What the quality statement means for service providers, healthcare practitioners, and commissioners
Service Servicepro providers viders ensure that systems are in place for relatives of people with a confirmed diagnosis of monogenic FH to be offered DNA testing through a nationwide, systematic cascade process.
Specialists with e Specialists with expertise in FH xpertise in FH offer DNA testing to relatives of people with a confirmed diagnosis
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of monogenic FH through a nationwide, systematic cascade process.
Commissioners Commissioners ensure that they commission services that offer DNA testing to relatives of people with a confirmed diagnosis of monogenic FH, through a nationwide, systematic cascade process.
What the quality statement means for patients, service users and carers
Relativ Relatives of people with a confirmed diagnosis of FH and a known DNA mutation es of people with a confirmed diagnosis of FH and a known DNA mutation are offered DNA testing themselves as part of a national scheme.
Source guidance
Familial hypercholesterolaemia: identification and management (NICE guideline CG71), recommendation 1.2.1
Definitions of terms used in this quality statement
Familial h Familial hypercholesterolaemia (FH) ypercholesterolaemia (FH)
Monogenic FH Monogenic FH
Present when an autosomal dominant pattern of inheritance of elevated LDL-C levels is seen in the extended family of the proband (for example, on average 50% of first-degree relatives have elevated levels). In relatives, the age-and gender-specific diagnostic cut-offs in NICE's guideline on familial hypercholesterolaemia should be used because the Simon Broome diagnostic cut-offs are not appropriate for relatives. The diagnosis of monogenic FH can also be given when the index case carries a documented FH-causing mutation in the LDLR, APOB or PCSK9 genes.
Confirmed diagnosis of monogenic FH Confirmed diagnosis of monogenic FH
This requires evidence from DNA testing of an FH-causing mutation in the LDLR, APOB or PCSK9
genes. Before cascade testing is initiated in relatives, a diagnosis of monogenic FH in the index person should be confirmed by a specialist with expertise in FH.
Relativ Relatives es
At least first-and second-degree biological relatives and third-degree biological relatives if
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Quality statement 6: Drug treatment in adults Quality statement 6: Drug treatment in adults
Quality statement
Adults with familial hypercholesterolaemia (FH) receive lipid-modifying drug treatment to reduce LDL-C concentration by more than 50% from baseline.
Rationale
Lipid-modifying drug treatment reduces LDL-C levels and prevents the development of cardiovascular disease. Studies indicate that treatment that lowers LDL-C levels by more than 50% from baseline offers greater benefit for plaque stabilisation than treatment that is less effective at reducing LDL-C.
Quality measures
Evidence of local arrangements to ensure that adults with FH receive lipid-modifying drug treatment to reduce LDL-C concentration by more than 50% from baseline.
Data sour
Process Process
Proportion of adults with FH who receive appropriate lipid-modifying drug treatment.
Numerator -The number of people in the denominator receiving appropriate lipid-modifying drug treatment.
Denominator -The number of adults with FH.
Data sour
Outcome Outcome
Number of adults with FH whose LDL-C concentration is reduced by more than 50% from baseline within 1 year.
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Lipid-modifying drug treatment Lipid-modifying drug treatment
Lipid-modifying drug treatment should be given in accordance with the recommendations in NICE's guideline on familial hypercholesterolaemia, a summary of which is given below: to achieve the recommended reduction:
offer a high-intensity statin with the lowest acquisition cost as the initial treatment increase dose of statin to maximum licensed or tolerated dose ezetimibe monotherapy is recommended if the person is intolerant to statin therapy or there are contraindications to initial statin therapy co-administer ezetimibe with initial statin therapy when serum total or LDL-C concentration is not appropriately controlled and a change from initial statin therapy to an alternative statin is being considered.
Statins are classified as high intensity if they produce greater LDL-C reductions than simvastatin 40 mg (for example, simvastatin 80 mg and appropriate doses of atorvastatin and rosuvastatin).
Treatment for FH is usually provided by either a specialist with expertise in FH or a GP through a shared care arrangement.
Equality and diversity considerations
The statement has been restricted to adults only because there is currently no evidence on which to base any specific target for lowering LDL-C in children and young people under 16 years.
However, lipid-modifying drug treatment should be considered by the age of 10 years in line with NICE's guideline on familial hypercholesterolaemia.
Women with FH should be advised that lipid-modifying drug treatment should not be taken if they are planning to conceive or during pregnancy because of the risk of fetal abnormality. Women should be advised that lipid-modifying drug treatment should be stopped 3 months before they attempt to conceive. Women with FH should be advised about the potential risks and benefits of re-starting lipid-modifying drug treatment for the mother and breastfed infant. Resins are the only lipid-modifying drug treatment that should be considered during breastfeeding.
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Quality statement 7: Drug treatment in children Quality statement 7: Drug treatment in children
Quality statement
Children with familial hypercholesterolaemia (FH) are assessed for lipid-modifying drug treatment by a specialist with expertise in FH in a child-focused setting by the age of 10 years.
Rationale
Children with FH begin to develop cardiovascular disease before clinical signs appear, with thickening of the carotid artery wall identifiable by the age of 10 years. Once a child is diagnosed as having FH, it is important they should be assessed for lipid-modifying drug treatment as soon as possible. The assessment should include a discussion of the harms and benefits of different treatments. This allows children to start treatment as soon as it is appropriate and before significant atherosclerosis has developed.
Quality measures
Evidence of local arrangements to ensure that children with FH are assessed for lipid-modifying drug treatment by a specialist with expertise in FH in a child-focused setting by the age of 10 years.
Data sour
Process Process
Proportion of children with FH who are assessed for lipid-modifying drug treatment by a specialist with expertise in FH in a child-focused setting by the age of 10 years.
Numerator -The number of people in the denominator assessed for lipid-modifying drug treatment by a specialist with expertise in FH in a child-focused setting.
Denominator -The number of children with FH aged 10 years.
Data sour
What the quality statement means for service providers, healthcare practitioners, and commissioners
Service pro Service providers viders ensure that systems are in place for children with FH to be assessed for lipid-modifying drug treatment by a specialist with expertise in FH in a child-focused setting by the age of 10 years.
Specialists with e Specialists with expertise in FH in children and y xpertise in FH in children and young people oung people assess children with FH for lipid-modifying drug treatment in a child-focused setting by the age of 10 years.
Commissioners Commissioners ensure that they commission services in which specialists with expertise in FH assess children with FH for lipid-modifying drug treatment, in a child-focused setting, by the age of 10 years.
What the quality statement means for patients, service users and carers
Children with FH Children with FH have an assessment for possible drug treatment to reduce the low-density cholesterol (bad cholesterol) in their blood by a specialist in a children's department, by the age of 10 years.
Source guidance
Familial hypercholesterolaemia: identification and management (NICE guideline CG71), recommendation 1.3.1.20 Recording progress of cascade testing among relatives.
Definitions of terms used in this quality statement
Updating the family pedigree and noting changes in the coronary heart disease status of relatives.
Assessing any symptoms of coronary heart disease.
Assessing smoking status, and offering advice and information on smoking cessation services.
Measuring fasting lipid profile.
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Using the quality standard Using the quality standard
Quality measures
The quality measures accompanying the quality statements aim to improve the structure, process and outcomes of care in areas identified as needing quality improvement. They are not a new set of targets or mandatory indicators for performance management.
For further information, including guidance on using quality measures, please see how to use quality standards.
Levels of achievement
Expected levels of achievement for quality measures are not specified. Quality standards are intended to drive up the quality of care, and so achievement levels of 100% should be aspired to (or 0% if the quality statement states that something should not be done). However, NICE recognises that this may not always be appropriate in practice, taking account of safety, choice and professional judgement, and therefore desired levels of achievement should be defined locally.
Using other national guidance and policy documents
Other national guidance and current policy documents have been referenced during the development of this quality standard. It is important that the quality standard is considered by commissioners, providers, health and social care practitioners, patients, service users and carers alongside the documents listed in development sources.
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Div Diversity ersity, equality and language , equality and language During the development of this quality standard, equality issues have been considered and equality assessments are available.
Good communication between healthcare practitioners and people with familial hypercholesterolaemia (FH) is essential. Treatment, care and support, and the information given about it, should be culturally appropriate. It should also be accessible to people with additional needs such as physical, sensory or learning disabilities, and to people who do not speak or read
English. People with FH should have access to an interpreter or advocate if needed.
Commissioners and providers should aim to achieve the quality standard in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity and foster good relations. Nothing in this quality standard should be interpreted in a way that would be inconsistent with compliance with those duties. 
